Ma Lin-Feng, Fan Wei
State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, 510060, PR China.
Ai Zheng. 2009 Apr;28(4):425-30.
Malignant lymphoma has high 2-fluorine-18-fluoro-2-deoxy-D-glucose (18F-FDG) uptake. This study was to analyze 18F-FDG uptake of lymphoma lesions of various histological subtypes.
FDG PET/CT images of 102 naive lymphoma patients were analyzed. The maximal standardized uptake value (SUVmax) of every single lesion and the SUVmax of mediastinal blood pool were measured and used to calculate the mean T/MB value (tumor SUVmax /mediastinal SUVmax) of every patient. The mean T/MB value of the patients with the same subtype of lymphoma was calculated. The differences in T/MB value between Hodgkin's lymphoma (HL) and non-Hodgkin's lymphoma (NHL) patients, between HL and indolent NHL, invasive NHL patients, between B-cell NHL and NK/T-cell NHL patients, and between diffuse large B-cell lymphoma (DLBCL) patients of different stages were analyzed. The expression of Ki-67 in lymph nodes from four patients with relative low T/MB value was detected.
The T/MB values were 4.50+/-1.54 in HL patients and 5.21+/-2.86 in NHL patients (P=0.154). The T/MB value was significantly higher in invasive NHL patients than in HL and indolent NHL patients (P<0.001). The T/MB values were 5.29+/-3.00 in B-cell NHL patients and 4.91+/-2.30 in NK/T-cell NHL patients (P=0.57). There was also no significant difference between DLBCL patients of different stages. The positive rate of Ki-67 was lower in the four patients with relative low T/MB value than in positive control group.
18F-FDG uptake of lymphoma lesions is related to lymphoma invasion, but not related to cell origin and clinical stage. The low 18F-FDG uptake in four patients may be related to low expression of Ki-67.
恶性淋巴瘤对2-氟-18-氟-2-脱氧-D-葡萄糖（18F-FDG）摄取较高。本研究旨在分析不同组织学亚型淋巴瘤病灶的18F-FDG摄取情况。
分析102例初治淋巴瘤患者的FDG PET/CT图像。测量每个单一病灶的最大标准化摄取值（SUVmax）及纵隔血池的SUVmax，并用于计算每位患者的平均T/MB值（肿瘤SUVmax/纵隔SUVmax）。计算相同亚型淋巴瘤患者的平均T/MB值。分析霍奇金淋巴瘤（HL）与非霍奇金淋巴瘤（NHL）患者之间、HL与惰性NHL、侵袭性NHL患者之间、B细胞NHL与NK/T细胞NHL患者之间以及不同分期弥漫大B细胞淋巴瘤（DLBCL）患者之间T/MB值的差异。检测4例T/MB值相对较低患者淋巴结中Ki-67的表达。
HL患者的T/MB值为4.50±1.54，NHL患者为5.21±2.86（P=0.154）。侵袭性NHL患者的T/MB值显著高于HL和惰性NHL患者（P<0.001）。B细胞NHL患者的T/MB值为5.29±3.00，NK/T细胞NHL患者为4.91±2.30（P=0.57）。不同分期的DLBCL患者之间也无显著差异。4例T/MB值相对较低患者的Ki-67阳性率低于阳性对照组。
淋巴瘤病灶的18F-FDG摄取与淋巴瘤侵袭有关，但与细胞来源及临床分期无关。4例患者18F-FDG摄取较低可能与Ki-67低表达有关。
